Breaking News Instant updates and real-time market news.

F

Ford

$13.23

0.07 (0.53%)

, FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

20:06
01/15/18
01/15
20:06
01/15/18
20:06

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) is increasing its planned investments in electric vehicles to $11B by 2022, according to Reuters, citing chairman Bill Ford. This is up from the prior target of $4.5B by 2020, the report noted. Meanwhile, Fiat Chrysler (FCAU) CEO Sergio Marchionne said he has no plans to sell its Jeep business or split up the company, according to The Wall Street Journal. 2. Softbank (SFTBY) is planning to list its mobile phone unit SoftBank Corp. in Tokyo and overseas this year, possibly bringing in $18B, according to Nikkei Asian Review. The telecommunications giant is aiming to apply to the Tokyo Stock Exchange as early as the spring, the report added. 3. Dozens of companies presented driverless technology at the annual Consumer Electronics Show, Jon Swartz wrote in this week's edition of Barron's. But while optimism about the growth of the market comes as consumers appear to become more comfortable with self-driving "robo-taxis," the technology has not quite arrived, he notes, adding that autonomous cars are pricey and with drivers ready to take the wheel as a safety buffer. Among the players of the crowded road to the self-driving future are Alphabet (GOOG; GOOGL), Tesla (TSLA), BMW (BMWYY), Ford, Toyota Motor (TM), General Motors (GM), and Volkswagen (VLKAY), the report noted. 4. Sony's (SNE) "Jumanji: Welcome to the Jungle" maintained the top spot at the domestic box office for the second consecutive weekend, earning $28.1M from 3,849 theaters. The Dwayne Johnson and Kevin Hart-led remake has received an A- CinemaScore and got a 77% from Rotten Tomatoes. 5. Facebook (FB), Amazon (AMZN), Apple (AAPL), Netflix (NFLX), Alphabet, Vivendi (VIVHY), Franklin Resources (BEN), Pfizer (PFE), Amgen (AMGN), AbbVie (ABBV), Elli Lilly (LLY), Bristol-Myers Squibb (BMY), and Johnson & Johnson (JNJ) saw positive mentions in Barron's.

F

Ford

$13.23

0.07 (0.53%)

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

SFTBY

SoftBank

$40.35

-0.705 (-1.72%)

GOOG

Alphabet

$1,122.26

16.74 (1.51%)

GOOGL

Alphabet Class A

$1,130.65

18.6 (1.67%)

TSLA

Tesla

$336.22

-1.73 (-0.51%)

BMWYY

BMW

$36.52

0.835 (2.34%)

TM

Toyota

$137.20

0.29 (0.21%)

GM

General Motors

$44.07

-0.12 (-0.27%)

VLKAY

Volkswagen

$44.34

1.065 (2.46%)

FB

Facebook

$179.37

-8.4 (-4.47%)

AMZN

Amazon.com

$1,305.20

28.52 (2.23%)

AAPL

Apple

$177.09

1.81 (1.03%)

NFLX

Netflix

$221.23

3.99 (1.84%)

VIVHY

Vivendi

$28.42

-1.035 (-3.51%)

BEN

Franklin Resources

$44.53

0.59 (1.34%)

PFE

Pfizer

$36.54

-0.02 (-0.05%)

AMGN

Amgen

$185.04

3.08 (1.69%)

ABBV

AbbVie

$100.34

1.07 (1.08%)

LLY

Eli Lilly

$86.98

0.59 (0.68%)

BMY

Bristol-Myers

$62.81

0.34 (0.54%)

JNJ

Johnson & Johnson

$145.76

0.97 (0.67%)

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 03

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 05

    Mar

  • 18

    Mar

  • 25

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

F Ford
$13.23

0.07 (0.53%)

12/28/17
MSCO
12/28/17
NO CHANGE
MSCO
January to be busy for Autos and Shared Mobility names, says Morgan Stanley
Morgan Stanley analyst Adam Jonas previewed the January calendar for the Autos and Shared Mobility sector, noting that the Vegas CES takes place in the second week and the Detroit Auto Show occurs in the third week of next month. Judging from last year's shows and press releases in recent weeks, he expects "the vast majority" of prepared presentations will focus on autonomous driving, electric propulsion and new business models as companies seek to encourage recognition and valuation of "Auto 2.0 efforts" in the multiples of their stocks, he tells investors. Automakers covered by the firm include Fiat Chrysler (FCAU), Tesla (TSLA), General Motors (GM), Ferrari (RACE) and Ford (F). Auto suppliers covered include Magna (MGA), Goodyear Tire (GT), Adient (ADNT), Delphi Technologies (DLPH), Visteon (VC), BorgWarner (BWA), Aptiv (APTV) and Tenneco (TEN).
10/30/17
GSCO
10/30/17
DOWNGRADE
GSCO
Sell
Goldman sees 28% downside in GM, downgrades shares to Sell
Goldman Sachs analyst David Tamberrino downgraded General Motors (GM) to Sell from Neutral saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. He sees "outsized downside" to shares of GM and expects a negative earnings inflection in 2018. Ford's (F) recently refreshed F-Series leaves GM vulnerable to share loss in 2018, Tamberrino tells investors in a research note. The analyst views Ford shares as more fairly valued. He keeps a Neutral rating on the name while upping his target for the shares to $13 from $10.
10/31/17
MSCO
10/31/17
NO CHANGE
Target $10
MSCO
Underweight
Ford bull case view raised despite 'significant headwinds' at Morgan Stanley
Morgan Stanley analyst Adam Jonas raised his 2017 EPS estimate for Ford to near the midpoint of the company's guidance following its Q3 report and slightly increased his price target on the stock to $10 from $9. While he keeps an Underweight rating on Ford, stating that the headwinds it faces are significant, he also sees the "scope for an equally significant response" and raised his bull case to $25 from $18 given a sum-of-the-parts analysis under which he values Ford's truck business, including the F-series and others, at nearly $20 per share, Ford Europe, S. America and Asia Pacific at "slightly less than zero" and "Ford Future" at $3B, or 74c per Ford share.
12/21/17
OPCO
12/21/17
NO CHANGE
Target $9
OPCO
Outperform
TeleNav extension with Ford should remove overhang, says Oppenheimer
Craig-Hallum analyst Steven Dyer notes that TeleNav (TNAV) announced preliminary Q2 results and amended its current agreement with Ford (F), which he believes is net/net positive for the P&L and should be a catalyst for shares. The analyst thinks the extension with Ford removes a major overhang on shares as it provides visibility for the next three years. Dyer reiterates an Outperform rating on TeleNav's shares, while lowering his price target on the stock to $9 from $12.
FCAU Fiat Chrysler
$23.39

-0.03 (-0.13%)

01/05/18
JPMS
01/05/18
UPGRADE
JPMS
Overweight
Fiat Chrysler upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jose Asumendi upgraded Fiat Chrysler to Overweight and raised his price target for the shares to EUR 21 from EUR 14.60. The analyst believes fiscal 2018 will be an "exceptional year" for the company, where it will renew 40% of its North American production, improving margins across all regions and become debt free "at last." He also sees Fiat as the largest beneficiary of the recently implemented U.S. tax reform.
11/10/17
11/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Buy from Hold at Needham with analyst Kevin Caliendo saying the stock's risk/reward is favorable, especially if CVS is able to consummate the reported merger with Aetna (AET). 2. Kohl's (KSS) upgraded to Outperform from Neutral at Baird with analyst Mark Altschwager saying Kohl's improving product portfolio and strong loyalty position the company for the holiday season, while cost savings and inventory reductions provide free-cash-flow visibility near-term. 3. Fiat Chrysler (FCAU) upgraded to Neutral from Sell at Citi. 4. Comcast (CMCSA) upgraded to Action List Buy from Buy at TD Securities. 5. Hyatt (H) upgraded to Buy from Hold at Berenberg with analyst Stuart Gordon saying the potential returns from the company's real estate disposals are being underappreciated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/15/18
LEHM
01/15/18
NO CHANGE
LEHM
Barclays likes American Axle, Fiat Chrysler in 'back-to-basics world'
After the Consumer Electronics Show focused on autonomous driving, Barclays analyst Brian Johnson expects the North American International Auto Show in Detroit "will get back to the here and now earnings drivers." The focus will be on trucks, tariffs, and taxes, Johnson tells investors in a research note on the U.S. Autos & Auto Parts sector. This includes a focus on key pickup truck launches, the potential for a North American Free Trade Agreement withdrawal to re-impose tariffs on autos and auto parts, and the impact of tax reform on earnings. In this "back-to-basics world," Johnson likes shares of American Axle (AXL) and Fiat Chrysler (FCAU). He sees Fiat as benefiting the most from tax reform and notes American Axle, his top pick, is the most levered to the U.S. large pickup market of any supplier he covers. The analyst says he's more confident in his Top Pick call and $25 price target on American Axle.
SFTBY SoftBank
$40.35

-0.705 (-1.72%)

01/23/17
JPMS
01/23/17
NO CHANGE
JPMS
JPMorgan says odds of T-Mobile, Sprint merger have 'increased dramatically'
JPMorgan analyst Philip Cusick believes T-Mobile (TMUS), Sprint (S) and DISH (DISH) are in play and that a combination of any of them could happen. In addition, each of the three companies could become targets for larger wireless players, domestic cable companies, Internet giants and foreign buyers, Cusick tells investors in a research note. He thinks the likelihood for a Sprint and T-Mobile tie-up in the near term has "increased dramatically" since September, from 10% to over 35%, including now a greater than 50% chance of announcement and 70% chance of approval if announced. Parents Softbank (SFTBY) and Deutsche Telekom (DTEGY) have increased their preference for a deal in the last six months and that the value of $5B of annual synergies "is enough to smooth over most disagreements on relative value," Cusick contends. He sees the most likely case as Sprint/Softbank buying T-Mobile, but feels a more even merger or even Deutsche Telekom/T-Mobile paying a premium to retain a majority of the combined company is possible.
11/06/17
SBSH
11/06/17
NO CHANGE
Target $75
SBSH
Buy
Citi trims T-Mobile, Sprint targets after merger talks cease
Citi analyst Michael Rollins lowered his price target for Buy-rated T-Mobile (TMUS) to $75 from $77 and for Neutral-rated Sprint (S) to $7.50 from $9.00 after the companies ceased talks to merge. He sees T-Mobile as "very comfortable" with its operating momentum and improving financial position and SoftBank (SFTBY) and Sprint (S) taking a more aggressive posture to pursue strategic partners. The analyst would not be surprised if SoftBank and Deutsche Telekom (DTEGY) revisit the merger talks in 6-12 months should Sprint and T-Mobile not find compelling strategic partners. Further, Rollins expects tower stocks like American Tower (AMT), SBA Communications (SBAC) and Crown Castle (CCI) to trade higher on expectations for greater capital expenditures now that the merger talks are over.
07/31/17
JPMS
07/31/17
NO CHANGE
Target $450
JPMS
Overweight
Charter offer would likely have to be at least $500 per share, says JPMorgan
JPMorgan analyst Philip Cusick believes SoftBank (SFTBY) is one of the few companies that could offer a big enough price to take control of Charter Communications (CHTR). While a deal is not very likely, Softbank Chairman Masayoshi Son "is never to be counted out as a buyer," Cusick tells investors in a research note. He believes a Charter acquisition offer would likely have to be in the $500 per share or higher range. Charter shares in premarket trading are up $31.74 to $402 after the Wall Street Journal reported Friday night that SoftBank has interest in merging the company with Sprint. Cusick estimates annual synergies between Sprint (S) and Charter could be around $2B, with minimal cost to integrate versus a Sprint and T-Mobile (TMUS) merger "which would have more eventual cost savings but cost much more to integrate." A Sprint and Charter deal would not have a difficult regulatory review, the analyst believes. Cusick adds that if Charter looked like it was going to sell to Softbank, Comcast (CMCSA) would have to decide if it ever did want to buy Charter and "move more quickly with an even bigger premium."
08/16/17
SBSH
08/16/17
NO CHANGE
SBSH
Citi still views Sprint, T-Mobile merger as most likely
Citi analysts Michael Rollins and Jason Bazinet continue to expect 2017 to be the year of mergers and acquisitions in the Wireless space. Since attending SoftBank's (SFTBY) Q2 Investor event and meeting with T-Mobile US (TMUS) management, the analysts still view a merger scenario between Sprint (S) and T-Mobile as the most likely to emerge in the Wireless space. "We are getting the increasing sense from multiple companies in the category that the regulatory environment may be as good as it gets," Rollins and Bazinet write in a research note.
GOOG Alphabet
$1,122.26

16.74 (1.51%)

01/11/18
PIPR
01/11/18
NO CHANGE
Target $1300
PIPR
Overweight
Alphabet price target raised to $1,300 from $1,150 at Piper Jaffray
Piper Jaffray analyst Sam Kemp raised his price target on Alphabet (GOOG) to $1,300, saying Google Cloud Platform is gaining mindshare from smaller competitors in the public cloud space amid "ongoing feature improvements, accompanying platform evangelism, and adoption by younger companies". The analyst contends that as a #3 player in the field behind Amazon's (AMZN) AWS and Microsoft's (MSFT) Azure, GCP can still create "meaningful shareholder value" within the accelerating cloud environment. Kemp keeps his Overweight rating on Alphabet.
01/12/18
MSCO
01/12/18
NO CHANGE
MSCO
Morgan Stanley most bullish on Amazon in large-cap internet
Morgan Stanley analyst Brian Nowak issued his 2018 outlook for U.S. internet names, saying among the large caps he is bullish on Amazon (AMZN) as he sees growing high margin revenues leading to upward revisions of estimates for the company. He is also positive on Facebook (FB), contending that core Facebook ad unit pricing can rise over 20% in 2018 and Instagram can add about $16B in ad revenue. Nowak also keeps an Overweight rating on Alphabet (GOOG), as he expects innovation to drive beats on revenue and profits. He has a $1,250 price target on Amazon, $215 price target on Facebook and a $1,210 target on Alphabet.
01/12/18
RHCO
01/12/18
NO CHANGE
Target $1250
RHCO
Buy
Alphabet price target raised to $1,250 from $1,180 at SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and raised his price target on Alphabet to $1,250 as part of his "Favorite Internet Stocks; Bullish Thesis Strengthened" research note. Squali says the company represents "one of the best plays" on macro economy trends amid a shift to digital advertising, rising consumption of video, and growing use of cloud computing. The analyst also notes several of Alphabet's longer-term initiatives such as self-driving cars with Waymo and smart home technology with Nest.
01/11/18
PIPR
01/11/18
NO CHANGE
PIPR
Overweight
Amazon's AWS still the leading public cloud offering, says Piper Jaffray
Piper Jaffray analyst Michael Olson reported that the firm's 2018 survey of CIOs shows that Amazon's (AMZN) AWS remains the leading public cloud offering in terms of revenue and scale and is tied with Microsoft's (MSFT) Azure for mindshare, which is a change from last year when AWS had lost some mindshare amid "early-2017 hype" regarding the maturation of Azure's offering. 90% of CIOs surveyed intend to increase AWS spending in 2018, which is up from 87% in 2017, Olson added. Azure maintained mindshare and Google Cloud Platform (GOOG) saw a significant step up in mindshare, while smaller cloud providers rapidly lose mindshare, noted Olson.
GOOGL Alphabet Class A
$1,130.65

18.6 (1.67%)

TSLA Tesla
$336.22

-1.73 (-0.51%)

01/08/18
BARD
01/08/18
UPGRADE
Target $152
BARD
Outperform
Albemarle upgraded to Outperform at Baird
As reported previously, Baird analyst Ben Kallo upgraded Albemarle (ALB) to Outperform from Neutral as he sees several upcoming catalysts that could drive the shares higher. Those catalysts include upcoming auto shows, which could display new electric cars that are drivers of lithium demand, potential auto announcements regarding electrification, and an ongoing ramp of Tesla's (TSLA) Model 3. Kallo raised his price target to $152 from $135 on Albemarle shares.
01/04/18
JPMS
01/04/18
NO CHANGE
Target $185
JPMS
Underweight
JPMorgan keeps $185 target on Tesla after production shortfall
JPMorgan analyst Ryan Brinkman reiterates an Underweight rating on Tesla shares with a $185 price target after the company's Model 3 deliveries in Q4 came in at 1,550, well below his 10,000 estimate. The stock in premarket trading is down 3%, or $11.00, to $306.25. The weaker than expected launch is likely the result of too optimistic assumptions on the company's part as regards the ease of manufacturing the Model 3, Brinkman tells investors in a research note titled "Model 3 Ramp Falls Far Short Again - Has Tesla Overestimated its Ease of Manufacture? Reiterate UW." The analyst believes that if the Q3 and Q4 production shortfalls stem from an overestimation of the ease to manufacture, then likely the associated cost to manufacture has been underestimated. He thinks this would reinforce his more bearish outlook on Tesla.
01/04/18
MSCO
01/04/18
NO CHANGE
Target $379
MSCO
Equal Weight
Morgan Stanley says Tesla Model 3 target shift 'should not at all be a surprise'
Morgan Stanley analyst Adam Jonas noted that Tesla posted delivery figures for Q4 that topped his forecast for each model line it offers, including the Model 3, adding that he thinks Tesla pushing out its production target of 5,000 Model 3 per week to the end of Q2 "should not at all be a surprise to the market." Jonas said his Q1 Model 3 delivery forecast of 8,000 units implies a pace of less than 700 per week, but Tesla appears to be currently producing the mass-market car at a pace well ahead of that implied in his earnings model. The analyst, who also noted that the company's Q4 deliveries suggest revenue 10% above his prior forecast, maintains an Equal Weight rating on the shares but said he would "buy the dip" in Tesla if the delayed Model 3 ramp causes weakness.
01/04/18
BARD
01/04/18
NO CHANGE
Target $411
BARD
Outperform
Tesla's upcoming catalysts keep Baird a buyer
Baird analyst Ben Kallo noted revised production targets from Tesla, but said the slower ramp provides insight into production bottlenecks. He believes the company will be able to ramp Model 3 production and that demand could accelerate with positive reviews from early customers. The analyst also believes the Model 3's total addressable market could be even larger than bulls project. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
BMWYY BMW
$36.52

0.835 (2.34%)

03/13/17
BERN
03/13/17
INITIATION
BERN
Market Perform
BMW initiated with a Market Perform at Bernstein
Price target EUR 85.
12/07/17
GSCO
12/07/17
DOWNGRADE
GSCO
Sell
BMW downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Stefan Burgstaller downgraded BMW to Sell and lowered his price target for the shares to EUR 85 from EUR 86. The analyst believes the company's product cycle could disappoint investors in 2018 and sees limited value over the next 12 months.
01/05/18
JPMS
01/05/18
DOWNGRADE
JPMS
Underweight
BMW downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jose Asumendi downgraded BMW to Underweight.
01/02/18
EVER
01/02/18
DOWNGRADE
EVER
In Line
BMW downgraded to In Line from Outperform at Evercore ISI
TM Toyota
$137.20

0.29 (0.21%)

08/24/17
RBCM
08/24/17
NO CHANGE
RBCM
Demand for Nvidia gaming chips remains strong, says RBC Capital
After conducting checks and reviewing Nvidia's (NVDA) 10-Q, RBC Capital analysts Mitch Steves and Amit Daryanani say that demand for Nvidia's gaming chips "remains healthy" in the midst of strong demand from crypto-currency miners. The analysts add that the company's new deal with Toyota (TM) should boost its selling volumes in 2018-2019, and cause its average selling prices to rise towards the end of that period. They add that sales of the company's Volta chip "are beginning to ramp." The analysts keep an Outperform rating on Nvidia.
09/21/17
RBCM
09/21/17
NO CHANGE
RBCM
Nvidia likely to continue partnering with Tesla, says RBC Capital
After CNBC and other media outlets reported that Tesla (TSLA) would work with AMD (AMD) to improve its self-driving car chips, RBC Capital analyst Mitch Steves expects Nvidia to continue to work with Tesla and remain the dominant chip provider to the automaker. He expects "similar dynamics" to play out in the data center space, with AMD "winning some share" in the sector, and Nvidia "remaining as the de-facto standard and market share leader." He notes that Toyota (TM) and Uber both use Nvidia's technology, and he does not expect the loss of share at Tesla to impact the chip maker over the long-term. He keeps an Outperform rating on Nvidia.
10/04/17
SBSH
10/04/17
UPGRADE
SBSH
Buy
Toyota upgraded to Buy from Neutral at Citi
Citi analyst Arifumi Yoshida upgraded Toyota Motor to Buy and raised his price target for the shares to 8,800 yen from 6,800 yen. The analyst believes Toyota's market share in the U.S. is recovering and thinks its development trends in all-solid-state batteries can drive multiple expansion.
10/04/17
10/04/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Toyota (TM) upgraded to Buy from Neutral at Citi with analyst Arifumi Yoshida saying he believes Toyota's market share in the U.S. is recovering and thinks its development trends in all-solid-state batteries can drive multiple expansion. 2. Sanchez Energy (SN) upgraded to Neutral from Sell at Seaport Global with analyst Mike Kelly citing valuation. 3. Jack in the Box (JACK) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Bob Derrington saying the company is "increasing its focus" on "improving its business trends." 4. Lennar (LEN) upgraded to Buy from Neutral at MKM Partners with analyst Megan McGrath saying she believes that its margins are stabilizing. 5. Dollar Tree (DLTR) upgraded to Buy from Neutral at Cleveland Research with analyst Scott Bender saying checks indicate Family Dollar trends have improved "noticeably" in the third quarter driven by a combination of company specific initiatives including remodels, merchandising changes, and operational improvements, and a general improvement in dollar channel sales trends. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GM General Motors
$44.07

-0.12 (-0.27%)

12/19/17
12/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Outperform from Sector Perform at RBC Capital with analyst Joseph Spak citing "increased confidence on downturn resiliency" in 2018, noting that while he anticipates a decline in fullsize pickup truck sales, he does not see "GMNA profitability to be down as much as previously forecast". 2. Walmart (WMT) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying the stock has "more room to run" in 2018. 3. Ulta Beauty (ULTA) upgraded to Buy from Neutral at Buckingham with the firm saying they recommend adding to positions given "extremely" attractive valuation and better flow through profitability that will deliver 20%+ earnings growth over the next two years or more. 4. Cabot (CBT) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying the improving global supply/demand fundamentals, along with tighter emissions controls in China, warrant the rating change. 5. Altria Group (MO) upgraded to Buy from Hold at Berenberg with analyst Jonathan Leinster saying he assumes that the company's headline tax rate will decline from historical levels of 35-36% to 21-22% due to the Republicans' proposed U.S. corporate tax changes. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
MSCO
01/08/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says Cadillac, worth $13B to GM, can't be ignored for long
General Motors does not disclose profitability by brand, but Morgan Stanley analyst Adam Jonas believes Cadillac is probably larger and more profitable than recognized by most investors, he stated in a new note. The analyst, who values Cadillac at about $13B, or roughly $9 per GM share, believes this value cannot be ignored for long and he sees room for GM's current efforts to improve financial and strategic transparency for the brand to gain momentum. Jonas keeps an Equal Weight rating on GM shares.
12/19/17
RBCM
12/19/17
UPGRADE
Target $52
RBCM
Outperform
General Motors upgraded to Outperform at RBC Capital on downturn resiliency
As reported earlier, RBC analyst Joseph Spak upgraded Generat Motors to Outperform from Sector Perform and nudged his price target to $52 from $51. Spak cites "increased confidence on downturn resiliency" in 2018, noting that while he anticipates a decline in fullsize pickup truck sales, he does not see "GMNA profitability to be down as much as previously forecast". The analyst models FY18 EPS of $6.30, about 9% above consensus view.
VLKAY Volkswagen
$44.34

1.065 (2.46%)

01/05/18
JPMS
01/05/18
NO CHANGE
JPMS
Volkswagen removed from Focus List, Peugeot added at JPMorgan
JPMorgan analyst Jose Asumendi removed Volkswagen (VLKAY) from his firm's Analyst Focus List but keeps an Overweight rating on the name. The analyst added Peugeot (PUGOY) to the list.
01/04/18
DBAB
01/04/18
UPGRADE
DBAB
Buy
Volkswagen upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Tim Rokossa upgraded Volkswagen to Buy and raised his price target for the shares to EUR 210 from EUR 170. The analyst sees a mix shift towards SUVs benefitting free cash flow and sees 40% of a truck initial public offering.
11/29/17
SUSQ
11/29/17
INITIATION
Target $50
SUSQ
Positive
Navistar initiated with a Positive at Susquehanna
Susquehanna analyst Brendon Mason initiated Navistar (NAV) with a Positive rating as he sees the company emerging from its failed engine strategy and internal restructuring strategy with an improved risk paradigm. The analyst said its alliance with Volkswagen (VLKAY) provides both immediate relief and significant long-term potential, its progress on improved margins should continue, and demand and build rates are expected to be strong in 2018 and 2019. Mason has a $50 price target on Navistar shares.
09/27/17
BARD
09/27/17
NO CHANGE
Target $48
BARD
Outperform
Navistar story remains compelling, says Baird
Baird analyst David Leiker believes the Navistar story is in its early innings, with current results near breakeven but with big upside over the next two to three years. The analyst noted its higher market share, stronger than expected EBITDA contribution and order growth that outpaces the industry - all of which increases his conviction in the company. Leiker reiterated his Outperform rating and $48 price target on Navistar shares.
FB Facebook
$179.37

-8.4 (-4.47%)

01/12/18
OPCO
01/12/18
NO CHANGE
OPCO
Facebook weakness a buying opportunity, says Oppenheimer
Oppenheimer analyst Jason Helfstein believes the recent weakness in Facebook, caused by Facebook CEO Mark Zuckerberg saying it would change the newsfeed algorithm to prioritize Social content above Publisher content, is a buying opportunity, as it shows how important the Facebook platform has become for users. Helfstein also noted that this change would also give Facebook a way to remove some of the "fake news" content that has become problematic. The analyst maintained an Outperform rating on Facebook shares. In late morning trading, Facebook shares are down 4.14% to $179.97.
01/12/18
01/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt arguing there is currently "too much uncertainty" relating to the economic impact of the company's pending News Feed changes communicated in a post last night by CEO Mark Zuckerberg. 2. Snap (SNAP) downgraded to Underperform from Market Perform at Raymond James with analyst Aaron Kessler saying Snap is largely a Chat/Message app and not a camera company as it refers to itself. 3. Etsy (ETSY) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Nowak citing valuation as being too expensive compared to its peers and the stock's historical average. 4. Comcast (CMCSA) downgraded to Buy from Action List Buy at TD Securities with analyst Vince Valentin citing recent shares strength and to make room of new Action List addition Shaw Communications (SJR), where he now sees better upside potential. 5. Electronic Arts (EA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Brian Nowak citing disappointing "Star Wars: Battlefront 2" third party data. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/12/18
MSCO
01/12/18
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Facebook still has multiple revenue levers amid uncertainty
Morgan Stanley analyst Brian Nowak noted that Facebook has announced plans to change its News Feed algorithm, which will essentially result in lower time spent on the platform. However, it is difficult to gauge the net impact of these changes and it is also unknown when these changes started, as prior commentary suggests they may have already been impacting results, Nowak tells investors. While the incremental near-term uncertainty will make Facebook "a show-me story" over the next few quarters, Nowak sees the company having multiple levers of ad revenue growth and he keeps an Overweight rating and $215 price target on the shares.
01/12/18
KEYB
01/12/18
NO CHANGE
KEYB
Facebook selloff a buying opportunity, says KeyBanc
KeyBanc analyst Andy Hargreaves recommended buying Facebook on the selloff, saying the company remains inexpensive relative to its strong growth prospects. Hargreaves maintained an Overweight rating and $220 price target on Facebook shares.
AMZN Amazon.com
$1,305.20

28.52 (2.23%)

01/12/18
RHCO
01/12/18
NO CHANGE
Target $1400
RHCO
Buy
Amazon.com price target raised to $1,400 from $1,270 at SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and raised his price target on Amazon to $1,400 as part of his "Favorite Internet Stocks; Bullish Thesis Strengthened" research note. Squali says that while the stock is not cheap, it remains "fundamentally compelling" based on the management's focus on customer experience with selection and price as well as leveraging of technology to disrupt commerce and IT services. The analyst says Amazon can continue to grow disproportionately faster than peers and gain market share in several segments of the economy.
01/15/18
JEFF
01/15/18
INITIATION
Target $240
JEFF
Buy
Jefferies assumes Alibaba with Buy rating, ups target to $240
Jefferies analyst Karen Chan assumed coverage of Alibaba (BABA) with Buy rating and raised her firm's price target for the shares to $240 from $160. The stock closed Friday down 88c to $187.79. The analyst sees "multi-year legroom for growth" in both Alibaba's customer management and cloud revenue. Technology-enabled online and offline retail integration as well as overseas expansion "becomes the next frontier for growth," Chan tells investors in a research note partially titled "Redefining the Future of Commerce." The analyst believes Alibaba Cloud has a similar growth trajectory to Amazon Web Services (AMZN) despite a five-year time lag.
AAPL Apple
$177.09

1.81 (1.03%)

01/12/18
COWN
01/12/18
NO CHANGE
COWN
Cowen remains cautious near-term on Apple supply chain
Cowen analyst Karl Ackerman said he remains cautious near-term on the Apple (AAPL) supply chain following his review of the iPhone builds for calendar Q4. He said final iPhone builds held up well versus expectations, but he said his work reveals less of a tailwind from new iPhones versus 30 days ago. Ackerman previously cut his estimates on supply chain names Broadcom (AVGO), Qorvo (QRVO), and Skyworks (SWKS) and remains cautious on the names.
01/10/18
BARD
01/10/18
NO CHANGE
Target $190
BARD
Outperform
Apple quarter should be solid, next quarter could have risk, says Baird
Baird analyst William Power said he expects Apple's first quarter results to be solid. However, he thinks there may be some risk to second quarter forecasts due in part to a lack of iPhone X promotions. The analyst said he remains positive on the shares given Apple's continuing platform strength, multiple growth opportunities, and tax reform benefits. Power recommends being aggressive on dips and reiterated his Outperform rating and $190 price target on Apple shares.
01/10/18
FBCO
01/10/18
DOWNGRADE
Target $29
FBCO
Neutral
Dialog Semiconductor downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Achal Sultania downgraded Dialog Semiconductor (DLGNF) to Neutral from Outperform, citing slowing revenue growth, peak margins, Apple (AAPL) uncertainty. The analyst also lowered his price target on Dialog's shares to EUR29 from EUR43.
01/12/18
NOMU
01/12/18
NO CHANGE
Target $175
NOMU
Neutral
Apple less likely in post upside in Q2, says Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal says "solid" iPhone X demand and "rapid" supply chain improvements likely puts Apple's Q1 results at the high end of guidance. The analyst, however, believes the consensus expectation of an above-seasonal March quarter no longer appears conservative. iPhone X order cuts make upside versus above-seasonal Q2 estimates less likely, Kvaal tells investors in a research note. The analyst keeps a Neutral rating on Apple shares with a $175 price target.
NFLX Netflix
$221.23

3.99 (1.84%)

01/10/18
JPMS
01/10/18
NO CHANGE
Target $1385
JPMS
Overweight
Amazon can be $1 trillion company over time, says JPMorgan
Amazon.com (AMZN) has the potential to be a $1 trillion dollar company over time, as it remains early in the e-commerce and cloud secular shifts, JPMorgan analyst Doug Anmuth tells investors in a research note. The shares closed yesterday up $5.83 to $1,252.70, which represents a market capitalization of around $603 billion. The analyst says Amazon is investing in more major growth opportunities than any other company he covers. Anmuth views Amazon as a top pick for 2018 and upped his price target for the shares to $1,385 from $1,375. He reiterates an Overweight rating on the name. Amazon shares increased 56% in 2017, more than Netflix (NFLX), Facebook (FB) and Alphabet (GOOG, GOOGL), Anmuth points out. He thinks Amazon will outperform again in 2018.
01/11/18
01/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with an Overweight at Barclays. 2. Dollar Tree (DLTR) initiated with a Buy at Guggenheim. 3. Coupa Software (COUP) initiated with a Buy at Needham. 4. First Solar (FSLR) initiated with a Buy at Vertical Group. 5. Bellatrix Exploration (BXE) initiated with an Underperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/18
WELS
01/08/18
NO CHANGE
Target $250
WELS
Outperform
Netflix price target raised to $250 from $230 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for Netflix to $250 from $230 as he sees the potential for estimate upside. The analyst reiterates an Outperform rating on the shares.
01/11/18
LEHM
01/11/18
INITIATION
Target $245
LEHM
Overweight
Netflix initiated with an Overweight at Barclays
Barclays analyst Kannan Venkateshwar started Netflix with an Overweight rating and $245 price target. If subscriber growth is faster than content cost growth over time, Netflix could become one of the most successful media companies, Venkateshwar tells investors in a research note. He believes this is possible. The analyst does not see imminent risk of Netflix missing subscriber numbers.
VIVHY Vivendi
$28.42

-1.035 (-3.51%)

06/23/17
RAJA
06/23/17
UPGRADE
RAJA
Outperform
Vivendi upgraded to Outperform from Market Perform at Raymond James
11/13/17
JPMS
11/13/17
UPGRADE
JPMS
Overweight
Vivendi upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Marcus Diebel upgraded Vivendi to Overweight and raised his price target for the shares to EUR 40 from EUR 19.
01/25/17
LEHM
01/25/17
DOWNGRADE
LEHM
Underweight
Vivendi downgraded to Underweight from Equal Weight at Barclays
Price target EUR 17.50.
BEN Franklin Resources
$44.53

0.59 (1.34%)

03/17/17
03/17/17
NO CHANGE

Underweight
Morgan Stanley cuts T. Rowe, Franklin Resources to sell with fees seen at risk
As previously reported, Morgan Stanley analyst Michael Cyprys downgraded asset managers T. Rowe Price (TROW) and Franklin Resources (BEN), each to Underweight from Equal Weight, citing his belief that structural changes in the industry could compress traditional managers' fees by 10-15% over the next 3-5 years. Cyprys sees the gap between alternative and traditional asset managers as widening and increasingly prefers the alternative managers, which he sees having less exposure to disruption. The analyst, who also has Underweight ratings on Janus Capital (JNS) and Waddell & Reed (WDR), keeps Overweight ratings on only BlackRock (BLK) and Invesco (IVZ) among the asset managers he covers.
09/08/17
LEHM
09/08/17
INITIATION
Target $40
LEHM
Underweight
Franklin Resources initiated with an Underweight at Barclays
Barclays analyst Jeremy Campbell started Franklin Resources with an Underweight rating and $40 price target. The analyst initiated U.S. Brokers, Asset Managers & Exchanges with a Neutral industry view.
04/11/17
MSCO
04/11/17
NO CHANGE
MSCO
Consolidation wave approaching Asset Management industry, says Morgan Stanley
Morgan Stanley analyst Michael Cyprys sees multiple headwinds - including distribution challenges, intensifying fee pressure, new regulation, and a weak organic growth outlook for active management - facing Asset Managers and believes that while M&A may not solve the challenges it can help firms adapt to better navigate the shifting landscape. The analyst, who believes "this time is different," thinks scale can help and predicts a wave of large-scale consolidation is approaching for the industry. Brokers and Asset Managers covered by Morgan Stanley include WisdomTree (WETF), Waddell & Reed (WDR), T. Rowe Price (TROW), Franklin Resources (BEN), Janus Capital (JNS), BlackRock (BLK) and Invesco (IVZ).
07/24/17
WELS
07/24/17
DOWNGRADE
Target $50
WELS
Market Perform
Franklin Resources downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Christopher Harris downgraded Franklin Resources to Market Perform saying the "easy money" has already been made as the rate of flow improvement will slow. Further, the analyst believes the current valuation already reflects some of the potential tax reform catalyst. Harris keeps a $50 price target for the shares.
PFE Pfizer
$36.54

-0.02 (-0.05%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
AMGN Amgen
$185.04

3.08 (1.69%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
Piper highlights 'clockwork' drug price increases by Amgen, Biogen
Amgen (AMGN) and Biogen (BIIB) took price increases on a number of important franchise products effective January 1, 2018, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs." While political scrutiny of drug pricing tactics "may come and go," demand for dominant biologics and specialty therapies with truly differentiated profiles appears to remain relatively price inelastic, Raymond contends. He notes that Amgen raised Enbrel's price by 9.7% and Neulasta's price by 5%. Biogen raised Tecfidera's price by 8%, Avonex/Plegridy's price by 8% and Tysabri's price by 3%, the analyst notes, citing data from Wolters Kluwer Heath. Raymond keeps Overweight ratings on both Amgen and Biogen.
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
AbbVie joining peers with typical January price hikes, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss noted that AbbVie (ABBV) took early-January price increases, highlighting that Humira saw a 9.7% increase that is similar in both timing and magnitude to last year's increase and once again "exactly" matches Amgen's (AMGN) Enbrel. In a note of his own earlier this morning titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs," Piper Jaffray analyst Christopher Raymond highlighted that Amgen and Biogen (BIIB) also increased prices on a number of important franchise products effective January 1, 2018. Purkiss maintains his Overweight rating on AbbVie shares.
ABBV AbbVie
$100.34

1.07 (1.08%)

01/04/18
JEFF
01/04/18
NO CHANGE
Target $120
JEFF
Buy
Jefferies calls AbbVie top pick in Pharma, ups target to $120
Jefferies analyst Jeffrey Holford raised his price target for AbbVie to $120 from $115 and says the stock is his top pick in U.S. Large Cap Pharma. Positive estimate revisions tied to tax reform, the Mavyret launch and share repurchases put the company "in a strong position" to beat and raise through 2018, Holford tells investors in a research note. He believes the company's 2018 guidance is likely too conservative.
01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Enanta downgraded to Sector Perform at RBC Capital after 'considerable run'
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Enanta (ENTA) to Sector Perform from Outperform, saying his positive near-term thesis on Mavyret has now played out and the potential for long-term royalties from AbbVie (ABBV) are "baked into the stock". The analyst believes that the trajectory of the treatment is now better appreciated" by the Street, adding the stock is more likely to trade in line in the immediate term given the "limited patient data for the NASH/PBC and RSV programs in 2018".
LLY Eli Lilly
$86.98

0.59 (0.68%)

01/05/18
ARGS
01/05/18
UPGRADE
ARGS
Buy
Eli Lilly upgraded to Buy from Hold at Argus
01/05/18
ARGS
01/05/18
UPGRADE
Target $115
ARGS
Buy
Eli Lilly upgraded to Buy at Argus on multiple 2018 catalysts
As noted earlier, Argus analyst David Toung upgraded Eli Lilly to Buy from Hold with a price target of $115. Toung cites possible "blockbuster" launches of baricitinib and galcanezumab as well as a regulatory update on galcanezumab as potential 2018 catalysts. The also analyst expects Eli Lilly's Trulicity, Basaglar, Jardiance, Cyramza, and Lartruvo sales to help offset slower sales of older drugs Cialis, Forteo, Effient that have lost patent protection. Toung raises his FY18 EPS forecast for Eli Lilly to $4.64 from $4.40.
12/14/17
BMOC
12/14/17
NO CHANGE
Target $73
BMOC
Underperform
Eli Lilly longer term risks remain, says BMO Capital
BMO Capital analyst Alex Arfaei says that while the FY18 outlook for Eli Lilly was slightly better than expected on the top line, longer term risks for the company may become "more evident" next year. Arfaei anticipates more concerns about the diabetes franchise, adding that his forecasts for the segment are still well below consensus starting with 2019. The analyst keeps his Underperform rating with a $73 price target.
01/05/18
01/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Overweight from Equal Weight at Morgan Stanley WITH analyst Ricky Goldwasser contending that its planned acquisition of Aetna (AET) creates a path for accelerating EBIT growth from synergies and new Aetna membership. 2. Eli Lilly (LLY) upgraded to Buy from Hold at Argus with analyst David Toung citing possible "blockbuster" launches of baricitinib and galcanezumab as well as a regulatory update on galcanezumab as potential 2018 catalysts. 3. Lowe's (LOW) was upgraded to Overweight from Equal Weight and Target (TGT) was upgraded to Equal Weight from Underweight at Barclays. 4. Foot Locker (FL) upgraded to Buy from Neutral at Buckingham with analyst Scott Krasik saying he believes key product assortments are improving and expects an inflection in comparables by the second quarter. 5. Jack in the Box (JACK) upgraded to Neutral from Sell at Goldman Sachs with analyst Karen Holthouse saying the company is a "strong beneficiary" of tax reform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$62.81

0.34 (0.54%)

11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
JNJ Johnson & Johnson
$145.76

0.97 (0.67%)

12/13/17
LEER
12/13/17
NO CHANGE
Target $120
LEER
Outperform
Myeloma data good for Johnson & Johnson, neutral to Celgene, says Leerink
Leerink analyst Geoffrey Porges notes that during the late breaking abstract session at ASH a "very impressive" dataset was presented highlighting that the addition of Darzalex to standard of care combination VMP improves survival outcomes in newly diagnosed myeloma patients who are ineligible for transplant. The analyst points out that it is no secret that Johnson & Johnson (JNJ) would like to move daratumumab into frontline therapy in myeloma, and this trial is its best near-term opportunity. Porges believes that the trial success is positive for Johnson & Johnson/daratumumab and neutral for Celgene (CELG)/Revlimid. He reiterates an Outperform rating and $120 price target on Celgene's shares.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.

TODAY'S FREE FLY STORIES

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:26
02/24/18
02/24
16:26
02/24/18
16:26
Hot Stocks
Buffett believes Berkshire can handle $400B mega-catastrophe »

In his annual letter to…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:19
02/24/18
02/24
16:19
02/24/18
16:19
Periodicals
Buffet says laments inability to find targets for Berkshire to buy, Reuters says »

Warren Buffett lamented…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

16:16
02/24/18
02/24
16:16
02/24/18
16:16
Periodicals
Berkshire Hathaway reports record profit fueled by tax reform, Reuters says »

Berkshire Hathaway…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$32.66

0.55 (1.71%)

16:12
02/24/18
02/24
16:12
02/24/18
16:12
Periodicals
Twitter's SoundCloud investment officially wiped out, Recode reports »

Twitter has written off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

AAPL

Apple

$175.50

3 (1.74%)

16:08
02/24/18
02/24
16:08
02/24/18
16:08
Periodicals
Apple to store sensitive encryption keys in China, WSJ reports »

Apple will start to store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.98

0.09 (0.22%)

16:00
02/24/18
02/24
16:00
02/24/18
16:00
Periodicals
Volkswagen's U.S. unit settles emissions suit, Reuters reports »

Volkswagen's unit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

, UAL

United Continental

$67.57

0.87 (1.30%)

15:56
02/24/18
02/24
15:56
02/24/18
15:56
Periodicals
Delta, United Airlines cut ties with NRA, Reuters reports »

Delta Air Lines (DAL) and…

DAL

Delta Air Lines

$53.46

0.91 (1.73%)

UAL

United Continental

$67.57

0.87 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 30

    May

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

, BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

15:53
02/24/18
02/24
15:53
02/24/18
15:53
Earnings
Berkshire Hathaway reports Q4 operating EPS $3,338, consensus $2,622.23 »

Reports FY17 operating…

BRK.A

Berkshire Hathaway

$304,020.01

2616.01 (0.87%)

BRK.B

Berkshire Hathaway

$202.76

2.03 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.70

0.33 (0.35%)

, T

AT&T

$36.72

0.25 (0.69%)

15:44
02/24/18
02/24
15:44
02/24/18
15:44
Periodicals
May be time to consider Time Warner, Barron's says »

Time Warner (TWX) shares…

TWX

Time Warner

$94.70

0.33 (0.35%)

T

AT&T

$36.72

0.25 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

JKHY

Jack Henry

$121.95

1.79 (1.49%)

12:59
02/24/18
02/24
12:59
02/24/18
12:59
Conference/Events
Jack Henry management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

PFBC

Preferred Bank

$64.05

0.86 (1.36%)

12:52
02/24/18
02/24
12:52
02/24/18
12:52
Conference/Events
Preferred Bank management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

  • 24

    Sep

R

Ryder

$74.54

0.19 (0.26%)

12:47
02/24/18
02/24
12:47
02/24/18
12:47
Conference/Events
Ryder management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

ASPU

Aspen Group

$8.85

1.48 (20.08%)

12:29
02/24/18
02/24
12:29
02/24/18
12:29
Conference/Events
Aspen Group to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

TWTR

Twitter

$32.66

0.55 (1.71%)

, AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

10:47
02/24/18
02/24
10:47
02/24/18
10:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWTR

Twitter

$32.66

0.55 (1.71%)

AOBC

American Outdoor Brands

$10.00

-0.12 (-1.19%)

RGR

Sturm, Ruger

$49.90

0.9 (1.84%)

X

U.S. Steel

$43.52

0.54 (1.26%)

STLD

Steel Dynamics

$47.47

-0.53 (-1.10%)

NUE

Nucor

$66.94

-0.01 (-0.01%)

AKS

AK Steel

$5.50

-0.12 (-2.14%)

AET

Aetna

$175.55

0.49 (0.28%)

ANTM

Anthem

$235.24

1.56 (0.67%)

CNC

Centene

$100.45

0.96 (0.96%)

CI

Cigna

$194.79

2.89 (1.51%)

HNT

Health Net

HUM

Humana

$271.19

3.38 (1.26%)

MOH

Molina Healthcare

$72.94

1.38 (1.93%)

UNH

UnitedHealth

$230.16

3.07 (1.35%)

WCG

WellCare

$192.05

0.03 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 07

    Mar

  • 13

    Mar

  • 16

    Apr

  • 30

    May

DBX

Dropbox

, SNAP

Snap

$17.45

-0.06 (-0.34%)

09:49
02/24/18
02/24
09:49
02/24/18
09:49
Periodicals
Dropbox IPO bodes well, Barron's says »

In a follow-up article…

DBX

Dropbox

SNAP

Snap

$17.45

-0.06 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

IPG

Interpublic Group

$24.24

0.3 (1.25%)

, OMC

Omnicom

$77.31

0.52 (0.68%)

09:42
02/24/18
02/24
09:42
02/24/18
09:42
Periodicals
Advertising companies cheaper than usual, Barron's says »

After a tumble last year,…

IPG

Interpublic Group

$24.24

0.3 (1.25%)

OMC

Omnicom

$77.31

0.52 (0.68%)

PUBGY

Publicis

$18.82

0.09 (0.48%)

WPP

WPP

$95.30

0.93 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 05

    Mar

MSFT

Microsoft

$94.06

2.33 (2.54%)

, INTC

Intel

$47.73

1.93 (4.21%)

09:36
02/24/18
02/24
09:36
02/24/18
09:36
Periodicals
Quantum computing soon to be reality, Barron's says »

Microsoft (MSFT) predicts…

MSFT

Microsoft

$94.06

2.33 (2.54%)

INTC

Intel

$47.73

1.93 (4.21%)

NVDA

Nvidia

$245.93

3.78 (1.56%)

MU

Micron

$46.53

2.28 (5.15%)

GOOG

Alphabet

$1,126.79

20.16 (1.82%)

GOOGL

Alphabet Class A

$1,128.09

18.19 (1.64%)

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 30

    May

AMZN

Amazon.com

$1,500.00

14.66 (0.99%)

09:26
02/24/18
02/24
09:26
02/24/18
09:26
Periodicals
Many downsides when Amazon's HQ2 comes to town, Barron's says »

As Amazon decides on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

BHGE

Baker Hughes

$28.03

-0.01 (-0.04%)

04:55
02/24/18
02/24
04:55
02/24/18
04:55
Conference/Events
Baker Hughes management to meet with UBS »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

GE

General Electric

$14.49

-0.01 (-0.07%)

18:49
02/23/18
02/23
18:49
02/23/18
18:49
Periodicals
General Electric could face DOJ action over subprime mortgages, Reuters says »

General Electric may face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEDU

Bright Scholar

$20.15

0.34 (1.72%)

18:30
02/23/18
02/23
18:30
02/23/18
18:30
Syndicate
Bright Scholar files to sell 10M American Depositary Shares »

Each ADS represents one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

, CMD

Cantel Medical

$115.34

2.45 (2.17%)

18:03
02/23/18
02/23
18:03
02/23/18
18:03
Periodicals
J&J sterilization unit draws bids from Cantel Medical, Medtronic, Bloomberg says »

Cantel Medical (CMD) and…

JNJ

Johnson & Johnson

$132.02

2.11 (1.62%)

CMD

Cantel Medical

$115.34

2.45 (2.17%)

MDT

Medtronic

$80.39

-0.02 (-0.02%)

KKR

KKR

$21.96

0.18 (0.83%)

CG

Carlyle Group

$23.15

-0.1 (-0.43%)

MMM

3M

$237.02

1.02 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 14

    Mar

  • 23

    Mar

  • 23

    Apr

  • 30

    May

AET

Aetna

$175.55

0.49 (0.28%)

, CVS

CVS Health

$68.16

0.16 (0.24%)

18:00
02/23/18
02/23
18:00
02/23/18
18:00
Hot Stocks
Aetna: CVS deal part of long-term solution toward value-based system »

According to prepared…

AET

Aetna

$175.55

0.49 (0.28%)

CVS

CVS Health

$68.16

0.16 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 30

    May

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:56
02/23/18
02/23
17:56
02/23/18
17:56
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$2.60

0.0301 (1.17%)

17:55
02/23/18
02/23
17:55
02/23/18
17:55
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.